Category Archives: Patent Eligibility (101)

Revised FC opinion maintains invalidity of one independent claim as claiming a natural law and nothing more but vacates and remands DC invalidity decision regarding second independent claim as including “positioning” limitation”

American Axle & Manufacturing, Inc. v. Neapco Holdings LLC, et al. Docket No. 2018-1763 NEWMAN, TARANTO, STOLL October 3, 2019 (revised July 30, 2020) Update (July 30, 2020): Original FC opinion affirmed the DC decision that AA’s claims are ineligible … Continue reading

Posted in Patent Eligibility (101), Patentability | Leave a comment

DC patent ineligibility holding for Illumina’s fetal DNA-related claims again reversed

Illumina, Inc., Sequenom, Inc. v. Ariosa Diagnostics, Inc. et al. Docket No. 2019-1419 LOURIE, MOORE, REYNA March 17, 2020 Update (August 3, 2020): In a revision of its March 17, 2020 opinion reversing the DC’s 101 ineligibility decision, the FC … Continue reading

Posted in Patent Eligibility (101), Patentability | Leave a comment

Uniloc claim ineligible under § 101 as abstract, claim includes “no specific asserted improvements”

Cisco Systems, Inc. v. Uniloc 2017 LLC Docket No. 2019-2048 MOORE, O’MALLEY, TARANTO May 13, 2020 Non-Precedential Brief Summary: DC finding of patent ineligibility under § 101 affirmed (abstract idea since claim includes “no specific asserted improvements”). Summary: Uniloc appealed … Continue reading

Posted in Patent Eligibility (101), Patentability, Software | Leave a comment

Patent ineligibility decision reversed and remanded as claim is “not rendered ineligible for patent simply because it involves an abstract concept”

Cardionet, LLC et al. v. Infobionic, Inc. Docket No. 2019-1149 DYK, PLAGER, STOLL April 17, 2020 Brief Summary: DC patent ineligibility decision (section 101) reversed and remanded (“not rendered ineligible for patent simply because it involves an abstract concept”). Summary: … Continue reading

Posted in Patent Eligibility (101), Software | Leave a comment

DC patent ineligibility holding for Illumina’s fetal DNA-related claims reversed

Illumina, Inc., Sequenom, Inc. v. Ariosa Diagnostics, Inc. et al. Docket No. 2019-1419 LOURIE, MOORE, REYNA March 17, 2020 Brief Summary: DC finding that Illumina’s fetal DNA-related claims are patent ineligible reversed. Summary: Illumina appealed DC decision finding certain claims … Continue reading

Posted in Patent Eligibility (101), Patentability, Uncategorized | Leave a comment

Board CBM decisions of patent ineligibility affirmed (no improved computer functionality)

Customedia Technologies, LLC v. Dish Network Corp. et al. Docket No. 2018-2239 (CBM2017-00023), 2019-1000 (CBM2017-00032) PROST, DYK, MOORE March 6, 2020 Brief Summary: PTAB CBM decisions of patent ineligibility under 101 affirmed (e.g., “computers are invoked merely as a tool”, … Continue reading

Posted in Patent Eligibility (101), Software | Leave a comment

DC section 101 ineligibility decision reversed since the “the claimed invention is also directed to a non-abstract improvement”

Koninkijke KPN N.V. v. Gemalto, et al. and LG Electronics, Inc. Docket Nos. 2018-1863-65 DYK, CHEN, STOLL November 15, 2019 Brief Summary: DC finding of invalidity under § 101 reversed (claims “employs a new way of generating check data”). Summary: … Continue reading

Posted in Patent Eligibility (101), Software, Uncategorized | Leave a comment

Method of treatment claims patent ineligible under 101 for being “focused on screening for a natural law” (“the invention does not improve treatment…by taking advantage of the body’s natural process”)

INO Therapeutics LLC, et al. v. Praxair Distribution Inc., et al. Docket No. 2018-1019 DYK, CHEN, STOLL August 27, 2019 Non-precedential Brief Summary: DC finding that “method of treating patients” claims ineligible under section 101 affirmed as the claims are … Continue reading

Posted in Claim Construction, Patent Eligibility (101), Patentability, Uncategorized | Leave a comment

DC decision that wireless communication claims are patent eligible under section 101 reversed

The Chamberlain Group, Inc. v. Techtronic Industries Co., et al. (“TTI”) Docket No. 2018-2103, -2228 LOURIE, O’MALLEY, CHEN August 21, 2019 Brief Summary: DC finding of no invalidity under section 101 reversed; anticipation finding affirmed. Summary: TTI appealed DC grant … Continue reading

Posted in Patent Eligibility (101), Patentability, Software, Uncategorized | Leave a comment

Federal Circuit denies Athena’s petition for rehearing of finding that its claims relating to a correlation between antibodies to a protein (“MuSK”) and neurological disorders are invalid under § 101.

Athena Diagnostics, Inc. et al. v. Mayo Collaborative Services, LLC Docket No. 2017-2508 NEWMAN (D), LOURIE, STOLL February 6, 2019 (Petition for rehearing denied July 3, 2019) Update (July 3, 2019): Athena’s petition for rehearing regarding the invalidation under § … Continue reading

Posted in Patent Eligibility (101), Patentability | Leave a comment